Salicylate ototoxicity in patients with rheumatoid arthritis: a controlled study.
Open Access
- 1 February 1988
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 47 (2), 134-137
- https://doi.org/10.1136/ard.47.2.134
Abstract
Tinnitus or subjective hearing loss, or both, were reported by 61 of 134 (45%) patients with rheumatoid arthritis (RA) taking regular salicylates and by 73 of 182 (40%) untreated healthy subjects. In the patients with RA mean salicylate levels were not higher in those with tinnitus than in those without tinnitus, but levels were significantly higher in those with subjective hearing loss than in those with no symptoms. Twenty five per cent of the patients with RA had tinnitus or subjective hearing loss with salicylate levels less than 1.42 mmol/l. Audiometric responses in 31 patients correlated poorly with symptoms. Tinnitus and subjective hearing loss may be too non-specific to be reliable as tools for adjusting the salicylate level into the therapeutic range.This publication has 7 references indexed in Scilit:
- CONTROLLED TRIAL OF CLINICAL UTILITY OF SERUM SALICYLATE MONITORING IN RHEUMATOID-ARTHRITIS1984
- Tinnitus as an Indication of Therapeutic Serum Salicylate LevelsJAMA, 1973
- A Pilot Survey of Hearing Loss in Patients with Rheumatoid ArthritisScandinavian Journal of Rheumatology, 1972
- Variations of serum concentrations and half‐life of salicylate in patients with rheumatoid arthritisArthritis & Rheumatism, 1971
- Salicylate OtotoxicityNew England Journal of Medicine, 1965
- A Rapid Method for the Determination of Salicylates in Serum or Plasma*American Journal of Clinical Pathology, 1947